Reappointment of cost auditors to conduct audit of the cost records of the Company for the financial year 2026-27, is submitted.

August 03, 2026 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 526783 Dear Sir / Madam, Subject: Outcome of the Board meeting held on August 03, 2026 In continuation of our letter dated July 28, 2026, regarding the captioned subject and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, August 03, 2026, has inter alia, considered and approved: A. Unaudited Financial Results of the Company for the quarter ended June 30, 2026 Pursuant to Regulation 33 of the SEBI Listing Regulations, the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 (“Financial Results”), along with the Limited Review Report issued by the Statutory Auditors of the Company are enclosed. Further, the Financial Results shall be published in the newspapers in compliance with Regulation 47 of the SEBI Listing Regulations and the same will also be available on the website of the Company at www.dragarwals.co.in. B. Re-appointment of M/s. B Y & Associates, Practicing Cost Accountants, as the Cost Auditors of the Company for the financial year 2026-27 In accordance with the provisions of Section 148 of the Companies Act, 2013, read with the Companies (Cost Records and Audit) Rules, 2014, and as recommended by the Audit Committee, M/s. B Y & Associates, Practicing Cost Accountants, (Firm Registration No. 003498) were re- appointed as the Cost Auditors to conduct the audit of the Cost Records of the Company for the financial year 2026-27. The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the aforesaid re-appointment of Cost Auditor are enclosed herewith as Annexure I. The meeting commenced at 03:00 P.M. IST and concluded at 03:45 P.M. IST. Kindly take the above information on record. For Dr. Agarwal’s Eye Hospital Limited Meenakshi Jayaraman Company Secretary and Compliance Officer Encl.: as above S.R. BATL/80/ & ASSOCIATES LLP 10th Floor, Tidel Park "A" Block, North Wing Chartered Accountants No. 4, Rajiv Gandhi Salai Taramani, Chennai -600 113 India Tel: +9144 6117 9000 Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Dr. Agarwal's Eye Hospital Limited 1. We have reviewed the accompanying statement of unaudited financial results of Dr. Agarwal's Eye Hospital Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. S.R. Batlibof & Associates LLP, a Limited Liability Partnership with LlP Identity No. AA8·4295 Regd. Office: 22, Camac Street, Block 'B', 3rd Floor, Kolkata·700 016 S.R. LLP BATLIBOI & ASSOCIATES Chartered Accountants 5. The comparative unaudited Ind AS financial information of the Company for the corresponding quarter ended June 30, 2025, included in these unaudited Ind AS financial results, were reviewed by the predecessor auditor who expressed an unmodified conclusion on those unaudited Ind AS financial information on August 12, 2025. For S.R. Batliboi & Associates LLP Chartered Accountants ICAI Firm registration number: 1011049W/E300004 per Aravind K Partner Membership No.: 221268 Chennai, Tamil Nadu August 03, 2026 UDIN: 26221268TPGDLC9581 Dr. Agarwal's Eye Hospital Limited DrAgarwals CIN: L85110TN1994PLC027366 Regd Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai 600 018 Eye Hospital Phone No, 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com (Amounts in INR Crores except EPSJ Statement of Unaudited Financial Results for the Quarter Ended June 30, 2026 Quarter Ended Year Ended S.No. Particulars 30.Jun-26 31-Mar-26 30.Jun-25 31-Mar-26 Unaudited Audited Unaudited Audited [Refer Not& 4) [Refer Note 3) 1 Income {a) Revenue from operations 142.97 12001 116.92 470.87 (b) Olher income 1.96 1.57 0.80 5.82 Total income 144.93 121.58 117.72 476.69 2 Expenses {a) Purchase of stock-in-trade 14.66 12.03 11.87 47.73 {b) Changes in inventories of stock-in-trade -(increase)/ decrease (1.06) {0.90) 0.38 (0.71 I (c) Consumption of surgical !ens including other consumables 16.55 13.84 13.89 54.44 (d) Consultancy charges for doctors 19.66 1604 15.39 6144 (e) Employee benefits expense 27.48 23.96 22.18 91.68 (f) Finance costs 2.77 1.96 4.16 11.88 (g} Depreciation and amortisation expense 11.49 12.09 10.58 45.64 {h) Other expenses 22.42 2131 16.08 70.98 Total expenses 113.97 100.33 94.53 383.08 3 Profit before tax (1-2) 30.96 21.25 23.19 93.61 Tax expense • Current tax (including tax pertaining to earlier periods) 7.67 4.89 5.92 23.47 -Deferred tax (net) (0.09) 0.12 0.01 004 4 Total tax expense 7.58 5.01 5.93 23.51 5 Net profit after tax for the period (3-4) 23.38 16.24 17.26 70.10 6 Other comptehensive income/ (toss) Items that will not be reclassified to the statement of profit and loss •Re-measurement gains/ (losses) on defined benefit plans (0.63) 0.19 0.06 0.03 -Tax on items that will not be reclassified to the statement of profit and loss O 16 (0.05) (0.02) (0.01) Total other comprehensive income/ (loss) (net of tax) (0,47) 0.14 0.04 0.02 7 Total comprehensive income (5+6) 22.91 16.38 17.30 70.12 8 Paid-up equity share capital (Face value INR 101-each) 4.83 4.83 4. [Showing first 8,000 characters — download PDF for full document]